• Sorafenib in ATRX-Aware Glioma Assays

  2026-08-29

  Sorafenib, also known as BAY-43-9006, is more informative in glioma experiments when ATRX status, pathway engagement, and tumor–stroma context are analyzed together. This guide develops a genotype-aware framework for using the compound as a cancer biology research tool rather than treating one viability IC50 as a universal measure of response.

• Nintedanib (BIBF 1120) for Translational Assays

  2026-08-28

  Build more informative angiokinase experiments with Nintedanib (BIBF 1120), from concentration-response screens to ATRX-stratified glioma studies. This guide connects receptor biology, combination testing, formulation control, and practical troubleshooting for cancer and fibrosis research.

• OLIG2 mRNA Drives Rapid hiPSC Oligodendrocyte Differentiatio

  2026-08-28

  Xu and colleagues developed a transgene-free strategy for directing human induced pluripotent stem cells toward oligodendrocyte progenitor cells using synthetic modified messenger RNA encoding the phospho-mutant transcription factor OLIG2S147A. Repeated delivery produced stable OLIG2 expression, rapid generation of NG2-positive progenitors, and oligodendrocytes capable of supporting remyelination in vivo.

• ER Stress, GRP78/ATF6/CHOP, and Intestinal Stem Cells

  2026-08-27

  This study shows that tunicamycin-induced endoplasmic reticulum stress damages the mouse small-intestinal mucosa by reducing intestinal stem-cell abundance and differentiation capacity. Its main contribution is a mechanistic model linking GRP78/ATF6/CHOP activation and impaired p44/42 MAPK signaling with reduced crypt proliferation, increased apoptosis, and barrier disruption.

• Protease Inhibitor Cocktail: Assay-Safe Sample Prep

  2026-08-27

  Protease Inhibitor Cocktail EDTA-Free protects fragile protein readouts in biomaterial and inflammatory disease workflows. This guide connects inhibitor selection with hydrogel research, phosphorylation-sensitive assays, Western blotting, and co-immunoprecipitation controls.

• DFO: Reproducible Latent Fingerprint Detection

  2026-08-26

  This scenario-based guide explains how DFO (9H-1,8-Diazafluoren-9-one), SKU C6997, supports reproducible latent fingerprint chemical detection while clarifying its distinction from deferoxamine mesylate used in biological studies. It covers identity, solvent compatibility, storage, quality documentation, controls, and vendor-selection criteria for forensic and biomedical laboratory teams.

• P2RX1–CaMKII Signaling in Ph+ ALL Apoptosis

  2026-08-26

  Li et al. identify P2RX1 as a mechanistic regulator of mitochondrial apoptosis in Philadelphia chromosome-positive acute lymphoblastic leukemia, linking calcium imbalance and CaMKII hyperactivation to PI3K/Akt suppression. Their findings suggest that P2RX1 may represent both a marker of adverse disease biology and a potential vulnerability for improving tyrosine kinase inhibitor responses.

• NLRP10, Keratinocyte Survival, and AD Barrier Function

  2026-08-25

  The reference study defines NLRP10 as a human epidermal homeostasis regulator that connects atopic dermatitis risk genetics with keratinocyte survival, p63-dependent differentiation, and barrier integrity. Using patient skin samples and air-lift human skin equivalents, the authors show that NLRP10 restrains caspase-8 activation at the DISC and stabilizes p63, providing a mechanistic framework for understanding barrier failure in atopic dermatitis.

• Vincristine sulfate: Assay Workflows

  2026-08-25

  Build more reproducible vincristine assays by connecting microtubule mechanism to dose–response design, timing, and orthogonal readouts. This workflow distinguishes direct cytotoxicity from assay artifacts while supporting cancer research in leukemia, lymphoma, and solid-tumor models.

• Ruxolitinib phosphate: JAK/STAT Workflow Guide

  2026-08-24

  Build reproducible JAK1/JAK2 inhibition assays for cytokine biology, autoimmune disease models, and anaplastic thyroid cancer research. This guide connects practical dosing and troubleshooting with evidence that links STAT3 suppression to mitochondrial remodeling, apoptosis, and GSDME-associated pyroptosis.

• From PS Exposure to Mechanism in Ph+ ALL

  2026-08-24

  A translational framework for using Annexin V-Cy5/DAPI staining to connect P2RX1-driven mitochondrial apoptosis with actionable cell-death measurements in Philadelphia chromosome-positive acute lymphoblastic leukemia.

• Naftifine HCl for Reproducible Cell Assays

  2026-08-23

  A scenario-based guide to using Naftifine HCl in fungal and mammalian cell viability, proliferation, and cytotoxicity workflows. It explains solvent controls, assay-interference checks, protocol parameters, interpretation limits, and why SKU B1984 is a practical research-grade option.

• TG003: A Cdc2-like Kinase Inhibitor Workflow

  2026-08-22

  TG003 enables reversible interrogation of Clk-dependent phosphorylation, alternative splicing, and platinum-resistance biology in one adaptable workflow. Its strongest use is not as a single-target drug surrogate, but as a dose-controlled mechanistic probe paired with isoform-aware RNA assays, kinase readouts, and genetic controls.

• Dabigatran: From Thrombin Target to Assay Signal

  2026-08-22

  Dabigatran and Pradaxa provide a mechanistically defined route to thrombin inhibition. This guide connects molecular pharmacology, assay endpoint selection, physicochemical constraints, and translational interpretation for more reliable coagulation research.

• Anti Reverse Cap Analog for High-Expression mRNA

  2026-08-21

  Learn how orientation-specific capping with ARCA improves synthetic mRNA translation workflows, from reaction setup and quality control to troubleshooting low protein output. The guide also translates insights from a targeted mRNA nanoparticle study into practical assay choices for mRNA therapeutics research without assuming that ARCA was used in the published work.

7822 records 1/522 page Next 12345 下5页 Last page